Crossmark

Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study

Crossref DOI link: https://doi.org/10.1186/s12879-025-10961-z

Published Online: 2025-04-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Steinberg, Jonathan

Panicker, Gitika

Unger, Elizabeth R.

Blake, Ian

Lewis, Rayleen M.

Geis, Jesse

Bruden, Dana

Fischer, Marc

Markowitz, Lauri E.

Bruce, Michael G.
License Information

Text and Data Mining valid from 2025-04-30

Version of Record valid from 2025-04-30
More Information

Article History

Received: 1 March 2024

Accepted: 10 April 2025

First Online: 30 April 2025

Declarations

:

: This study was approved by the Alaska Area Institutional Review Board (#2016–12-054), the CDC Institutional Review Board (#7020), the Alaska Native Tribal Health Consortium, and Southcentral Foundation Research Review. Participants provided written informed assent and parents provided written informed consent.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below